Logo image of RNXT

RENOVORX INC (RNXT) Stock Fundamental Analysis

NASDAQ:RNXT - Nasdaq - US75989R1077 - Common Stock - Currency: USD

1.28  -0.07 (-5.19%)

After market: 1.32 +0.04 (+3.13%)

Fundamental Rating

3

Overall RNXT gets a fundamental rating of 3 out of 10. We evaluated RNXT against 555 industry peers in the Biotechnology industry. While RNXT has a great health rating, there are worries on its profitability. RNXT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RNXT has reported negative net income.
In the past year RNXT has reported a negative cash flow from operations.
RNXT had negative earnings in each of the past 5 years.
RNXT had a negative operating cash flow in each of the past 5 years.
RNXT Yearly Net Income VS EBIT VS OCF VS FCFRNXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

RNXT has a worse Return On Assets (-63.43%) than 61.26% of its industry peers.
Looking at the Return On Equity, with a value of -77.21%, RNXT is in line with its industry, outperforming 51.35% of the companies in the same industry.
Industry RankSector Rank
ROA -63.43%
ROE -77.21%
ROIC N/A
ROA(3y)-314.19%
ROA(5y)-236.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNXT Yearly ROA, ROE, ROICRNXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

RNXT's Gross Margin of 17.92% is fine compared to the rest of the industry. RNXT outperforms 72.97% of its industry peers.
The Profit Margin and Operating Margin are not available for RNXT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNXT Yearly Profit, Operating, Gross MarginsRNXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

RNXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
RNXT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RNXT has more shares outstanding
RNXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNXT Yearly Shares OutstandingRNXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RNXT Yearly Total Debt VS Total AssetsRNXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

An Altman-Z score of 3.90 indicates that RNXT is not in any danger for bankruptcy at the moment.
RNXT's Altman-Z score of 3.90 is fine compared to the rest of the industry. RNXT outperforms 75.50% of its industry peers.
There is no outstanding debt for RNXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.9
ROIC/WACCN/A
WACC8.93%
RNXT Yearly LT Debt VS Equity VS FCFRNXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 9.07 indicates that RNXT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.07, RNXT is in the better half of the industry, outperforming 74.23% of the companies in the same industry.
RNXT has a Quick Ratio of 9.07. This indicates that RNXT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.07, RNXT is in the better half of the industry, outperforming 74.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.07
Quick Ratio 9.07
RNXT Yearly Current Assets VS Current LiabilitesRNXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.00% over the past year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RNXT will show a very strong growth in Earnings Per Share. The EPS will grow by 24.74% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.8%
EPS Next 2Y18.17%
EPS Next 3Y25.45%
EPS Next 5Y24.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNXT Yearly Revenue VS EstimatesRNXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
RNXT Yearly EPS VS EstimatesRNXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNXT. In the last year negative earnings were reported.
Also next year RNXT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNXT Price Earnings VS Forward Price EarningsRNXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNXT Per share dataRNXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as RNXT's earnings are expected to grow with 25.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.17%
EPS Next 3Y25.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNXT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RENOVORX INC

NASDAQ:RNXT (6/27/2025, 8:00:02 PM)

After market: 1.32 +0.04 (+3.13%)

1.28

-0.07 (-5.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-13 2025-08-13
Inst Owners20.46%
Inst Owner Change845%
Ins Owners4.36%
Ins Owner Change14.77%
Market Cap46.81M
Analysts82
Price Target5.61 (338.28%)
Short Float %0.52%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.95%
Min EPS beat(2)-15.86%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)1.59%
Min EPS beat(4)-15.86%
Max EPS beat(4)18.3%
EPS beat(8)5
Avg EPS beat(8)11.85%
EPS beat(12)8
Avg EPS beat(12)7.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.33%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)36.11%
EPS NY rev (1m)-3.37%
EPS NY rev (3m)17.86%
Revenue NQ rev (1m)10.26%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-18.42%
Revenue NY rev (3m)315.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 195.04
P/FCF N/A
P/OCF N/A
P/B 3.56
P/tB 3.56
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.01
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.43%
ROE -77.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.92%
FCFM N/A
ROA(3y)-314.19%
ROA(5y)-236.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.07
Quick Ratio 9.07
Altman-Z 3.9
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y21.8%
EPS Next 2Y18.17%
EPS Next 3Y25.45%
EPS Next 5Y24.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.36%
OCF growth 3YN/A
OCF growth 5YN/A